Cost-efectiveness evaluation of tocilizumab in Romania setting

Ancuta, Ioana; Baculea, Simona; Szkulecka-Debek, Monika

doi:10.5233/mih.2009.0018

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, only a few countries (Hungary and Poland) have more formal HTA systems in place, while others are still in the early stages of implementing a national HTA body(s). As a result, there are only a few HTA evaluations of biological treatments in RA available [11–16,18]; not surprising, in view of the lack of country-specific data on cost of care and quality of life of RA patients.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries

Orlewska

Ancuta²,

Anić

et al. 2011

Med Sci Monit

View full text Add to dashboard Cite

SummaryBackgroundThe aim of this study was to assess and compare patients’ access to biologic anti-RA drugs in selected Central and Eastern European (CEE) countries and to analyze the determinants of differences between countries.Material/MethodsThis is a multi-country survey study, based on a combination of desk research and direct contact with national RA stakeholders. Data was collected using a pre-defined questionnaire. Affordability was measured using an affordability index, calculated comparing the index of health care expenditures to the price index, using Poland as an index of 1.ResultsThe percentage of patients on biologic treatment in 2009 was highest in Hungary (5% RA patients on biologic treatment), followed by Slovenia (4.5%), Slovakia (3.5%), Czech Republic (2.92%), Romania (2.2%), Estonia (1.8%), and Croatia, Serbia, Poland (below 1.5%). Infliximab, etanercept, adalimumab and rituximab were included in the reimbursement system in all countries, but abatacept and tocilizumab were included only in Slovakia. In Slovenia, public payer covered 75% of the price, and 25% is covered by supplementary health insurance; in Bulgaria public payer covered 50% of etanercept and adalimumab costs, and 75% of rituximab cost. In other countries, biologic drugs are reimbursed at 100%. Affordability index for biologic drugs was the lowest in Slovenia (0.4). In each country national guidelines define which patients are eligible for biologic treatment. Disease Activity Score (DAS28) of over 5.1 and failure of 2 or more disease-modifying anti-RA drugs, including methotrexate, are commonly used criteria.ConclusionsThe most important factors limiting access to biologic anti-RA treatment in the CEE region are macroeconomic conditions and restrictive treatment guidelines.

show abstract

Section: Resultsmentioning

confidence: 99%

“…In Romania, only 1 economic analysis was published [18]. In the cost-effectiveness analysis, 2 alternatives were compared – a sequence of treatment including either infliximab, etanercept or adalimumab, followed by rituximab, and a sequence of treatment including tocilizumab as first agent, followed by rituximab.…”

Section: Resultsmentioning

confidence: 99%

Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries

Orlewska

Ancuta²,

Anić

et al. 2011

Med Sci Monit

View full text Add to dashboard Cite

show abstract

“…Nonetheless, TCZ's favorable cost-effectiveness (from €13,220/QALY to €36,900/QALY) as a monotherapy Fig. 2 Cost-effectiveness scatterplot was demonstrated by findings of economic evaluations performed in the USA [40], Turkey [41], Spain [42], Portugal [43], Scotland [44], UK [45] and Romania [46]. A UK-based study [47], using a similar research design and model, reports an ICER of £7,289/QALY for TCZ first line and an ICER of £11,400/QALY for TCZ second line, leading to the notion that the current study's findings could be regarded rather conservative.…”

Section: Discussionmentioning

confidence: 97%

Cost-utility analysis of tocilizumab monotherapy in first line versus standard of care for the treatment of rheumatoid arthritis in Greece

et al. 2015

View full text Add to dashboard Cite

The study aims to evaluate the cost-effectiveness of adding tocilizumab (TCZ) first line to a treatment sequence for patients with active rheumatoid arthritis (RA), who had an inadequate response to one or more traditional synthetic disease-modifying antirheumatic drugs (DMARDs) and are intolerant to methotrexate (MTX), or in whom continued treatment with MTX is considered inappropriate. An individual simulation model was applied to project lifetime costs and outcomes for 10,000 patients from a payer's perspective. The analysis compared the standard treatment pathway (STP) with a similar pathway, where treatment was initiated with TCZ. QALYs were used as primary efficacy outcomes. Efficacy data were obtained from the ADACTA trial and a network meta-analysis. Clinical practice standards were derived from an expert panel of Greek rheumatologists. Results indicate that a treatment sequence starting with TCZ yields 1.17 more QALYs (9.38 vs. 8.21) at an additional cost of €3,744 (€119,840 vs. €86,096) compared with the STP. The incremental cost-effectiveness ratio was €28,837/QALY gained. Probabilistic sensitivity analysis confirms robustness of these findings as consistently below a threshold of €45,000. The results of the analysis suggest that TCZ, when used as a first-line biologic monotherapy, can be a cost-effective treatment option for the management of active RA in patients in need of biologic monotherapy.

show abstract

Cost-efectiveness evaluation of tocilizumab in Romania setting

Cited by 2 publications

References 0 publications

Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries

Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries

Cost-utility analysis of tocilizumab monotherapy in first line versus standard of care for the treatment of rheumatoid arthritis in Greece

Contact Info

Product

Resources

About